Abstract
Research in the field of erectile function and dysfunction has continued to expand rapidly. Based on the information available, some directions for future erectile dysfunction therapies can be identified. The first direction is improvement of current therapeutic principles. A second generation of orally active phosphodiesterase (PDE) inhibitors is being introduced, and further developments within this field can be expected. The recent introduction of apomorphine has opened the way for new dopamine receptor agonists. The second direction is combinations of existing therapeutic principles. Combinations of apomorphine and sildenafil and apomorphine and α1-adrenoceptor (AR) antagonists, for example, seem attractive and may have a therapeutic potential in patients not responding satisfactorily to single-drug treatment. Nitrosylated α1-AR antagonists, combining nitric oxide donation and α1- or α2-AR antagonism, are currently being evaluated. The third direction is new targets within the central nervous system. Melanocortin receptor agonists have shown promise not only in animal models, but also in preliminary studies in humans. Other possible targets, such as growth hormone-releasing peptide receptors, are being explored. The fourth direction is new peripheral targets. Rho-kinase antagonism and non-nitric oxide-mediated stimulation of soluble guanylyl cyclase have been suggested as possible new principles for drug development. The fourth direction is gene therapy. Progress has been made in intracavernosal somatic gene therapy and will probably continue. Still, problems remain, and advantages over conventional pharmacological therapies have to be demonstrated. The final direction is prevention strategies. Strategies to prevent cavernosal degeneration and/or to restore cavernosal function will be one of the most exciting challenges for future research.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Andersson, KE., Hedlund, P. New directions for erectile dysfunction therapies. Int J Impot Res 14 (Suppl 1), S82–S92 (2002). https://doi.org/10.1038/sj.ijir.3900797
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3900797
Keywords
This article is cited by
-
Preclinical effects of melanocortins in male sexual dysfunction
International Journal of Impotence Research (2008)
-
Rho kinase, a promising drug target for neurological disorders
Nature Reviews Drug Discovery (2005)
-
Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction
World Journal of Urology (2005)
-
Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients
Spinal Cord (2004)
-
Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie's disease
International Journal of Impotence Research (2004)